IN SILICO DOCKING STUDIES OF GALLIC ACID STRUCTURAL ANALOGUES AS BCL-XL INHIBITOR IN CANCER

  • Dian Maria Ulfa University of Indonesia
  • Ade Arsianti Department of Medical Chemistry, Faculty of Medicine, University of Indonesia
  • Maksum Radji Faculty of Pharmacy, University of Indonesia

Abstract

Objective: Apoptosis, or programed cell death, forms an important part of the cellular regulation machinery. The Bcl-2 protein family, comprising
proapoptotic and antiapoptotic members, forms an important part of the cells internal apoptotic pathway. Overexpression of the antiapoptotic
members of the family in a number of cancer cell lines renders them immune to apoptosis and the ability to survive under conditions of cellular stress.
Inhibition of the antiapoptotic members of the Bcl-2 family like Bcl-XL is, therefore, an interesting target for the development of anticancer therapy.

Methods: The structure of antiapoptotic Bcl-XL receptor (1YSG) was taken from PDB database. The 23-dimensional structure of gallic acid analogs
was designed. The Lipinski properties of gallic acid analogs were calculated using molsoft. Docking studies have been carried out through Autodock
4.0 software.

Results: Molecular docking analysis with gallic acid and their structural analogs showed propyl gallate, benzyl gallate, diallyl gallate, phenyl ethyl
gallate, and allyl gallate are more interactive and binding strongly than gallic acid at active site of Bcl-XL.

Conclusion: Further these five compounds should be considered as potential candidates for Bcl-XL inhibitor.

Keywords: Apoptosis, Bcl-2, Antiapoptotic Bcl-XL receptor, Gallic acid, Docking studies.

Author Biographies

Dian Maria Ulfa, University of Indonesia
Pharmacy Departmen
Ade Arsianti, Department of Medical Chemistry, Faculty of Medicine, University of Indonesia
Head of Chemistry Department

References

1. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335(6189):440-2.
2. Tóthová E, Fricova M, Stecová N, Kafková A, Elbertová A. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Neoplasma 2002;49(3):141-4.
3. Chavan M, Patil R, Baviskar D, Jain D. Role of apoptosis in human diseases. Int J Pharm Pharm Sci 2012;4(2):7-13.
4. Danial NN, Korsmeyer SJ. Cell death: Critical control points. Cell 2004;116(2):205-19.
5. Kirkin V, Joos S, Zörnig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004;1644(2-3):229-49.
6. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace AJ Jr. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000;60(21):6101-10.
7. Reed JC. Promise and problems of Bcl-2 antisense therapy. J Natl Cancer Inst 1997;89(14):988-90.
8. Letai A, Sorcinelli MD, Beard C, Korsmeyer SJ. Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell 2004;6(3):241-9.
9. Reddy MN, Reddy RN, Jamil K. Spicy anti-cancer spices: A review. Int J Pharm Pharm Sci 2015;7(11):1-6.
10. Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 2003;46(20):4259-64.
11. Verma S, Singh A, Mishra A. Gallic acid: Molecular rival of cancer. Environ Toxicol Pharmacol 2013;35(3):473-85.
12. Hsu CL, Huang SL, Yen GC. Inhibitory effect of phenolic acids on the proliferation of 3T3-L1 preadipocytes in relation to their antioxidant activity. J Agric Food Chem 2006;54(12):4191-7.
13. Merry DE, Korsmeyer SJ. Bcl-2 gene family in the nervous system. Annu Rev Neurosci 1997;20:245-67.
14. Hsu CL, Lo WH, Yen GC. Gallic acid induces apoptosis in 3T3-L1 pre-adipocytes via a Fas- and mitochondrial-mediated pathway. J Agric Food Chem 2007;55(18):7359-65.
15. You BR, Moon HJ, Han YH, Park WH. Gallic acid inhibits the growth of HeLa cervical cancer cells via apoptosis and/or necrosis. Food Chem Toxicol 2010;48(3):1334-40.
16. Cory S, Adams JM. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2(9):647-56.
17. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, et al. Structure of Bcl-xL-Bak peptide complex: Recognition between regulators of apoptosis. Science 1997;275(5302):983-6.
18. Dalafave DS, Prisco G. Inhibition of antiapoptotic BCL-XL, BCL-2, and MCL-1 proteins by small molecule mimetics. Cancer Inform 2010;9:169-77.
19. Sanner MF. Python: A programming language for software integration and development. J Mol Graph Model 1999;17(1):57-61.
20. Southan C, Stracz A. Extracting and connecting chemical structures from text sources using chemicalize.org. J Cheminform 2013;5(1):20.
21. Norgan AP, Coffman PK, Kocher JP, Katzmann DJ, Sosa CP. Multilevel parallelization of autodock 4.2. J Cheminform 2011;3(1):12.
22. Mukherjee P, Desai P, Zhou YD, Avery M. Targeting the BH3 domain mediated protein-protein interaction of Bcl-xL through virtual screening. J Chem Inf Model 2010;50(5):906-23.
Statistics
558 Views | 463 Downloads
Citatons
How to Cite
Ulfa, D. M., A. Arsianti, and M. Radji. “IN SILICO DOCKING STUDIES OF GALLIC ACID STRUCTURAL ANALOGUES AS BCL-XL INHIBITOR IN CANCER”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 4, Apr. 2017, pp. 119-22, doi:10.22159/ajpcr.2017.v10i4.16269.
Section
Original Article(s)